Pediatrics in Massachusetts

Commonwealth Diagnostics International (CDI) is a CLIA-certified clinical laboratory and diagnostic solutions provider specializing in hydrogen and methane breath testing for functional gastrointestinal disorders. CDI manufactures and distributes non-invasive, at-home breath test kits for the diagnosis of small intestinal bacterial overgrowth (SIBO), intestinal methanogen overgrowth (IMO), and carbohydrate malabsorption disorders (fructose, lactose, and sucrose malabsorption) in both adult and pediatric populations. The company operates proprietary gas chromatography instrumentation for test analysis and offers MyGI Gateway, a cloud-based digital platform for centralized management of patient orders, data, and results reporting. CDI delivers test results within one business day and maintains ISO 13485 certification, FDA registration, CE marking, and SAM.gov registration. The company serves gastroenterology practices, functional medicine providers, naturopathic doctors, and direct-to-consumer patients. CDI emphasizes clinically validated testing methods, peer-reviewed evidence, rapid turnaround, insurance coverage coordination (Medicare and commercial), and comprehensive provider and patient support resources including educational content, clinical guidelines, and billing assistance. The laboratory is located in Salem, Massachusetts.

Momentum Health Inc. develops Momentum Spine, a radiation-free 3D digital spine monitoring platform that uses smartphone video capture to create clinical-grade 3D spine scans and AI-powered analytics. The platform enables remote monitoring of complex spine conditions—particularly pediatric scoliosis (AIS) and adult spinal deformity—without requiring in-person X-rays or imaging center visits. The system employs deep-learning models to predict Cobb Angle (mean absolute error ~5–6°, comparable to inter-observer radiologist variation), track spinal asymmetry, assess brace compliance, analyze dynamic gait and posture metrics, and monitor whole-body sagittal alignment. Patients perform 45-second smartphone scans at home; clinicians access a secure web dashboard for real-time remote monitoring, triage, and data-driven intervention planning. Momentum Spine integrates into clinical workflows and supports Remote Therapeutic Monitoring (RTM) billing models. The company holds FDA 510(k) clearance (K232023, product code LDK) for the US market and Canadian Medical Device Establishment License (MDEL) clearance. The platform is SOC 2 Type 2 certified, HIPAA and PIPEDA compliant, and maintains ISO 13485 quality certification. Target markets include spine centers, hospital networks, pediatric orthopedic clinics, and research institutions. The company is based in Montreal, Canada, and serves leading healthcare systems including UCSF, NYP Och Spine, Cedars-Sinai, and Children's Hospital Los Angeles.

Summit International Medical Technologies is a specialty medical device manufacturer focused on critical care, anesthesia, dialysis, and neonatal markets. The company develops, manufactures, and distributes clinically innovative disposable and durable medical products designed to enhance patient safety and clinician efficiency while providing cost-effective care solutions. Key product lines include: Covalon AquaGuard moisture barrier systems for IV sites, PICC lines, and wound dressings; Parasol Medical fall prevention systems (wired and wireless) and DrySmart incontinence management pads; Starboard Medical temperature management probes for patient monitoring; Summit Medical AngelTip Safety Fistula for dialysis access; SternaSafe Uni sternum support braces for post-sternotomy recovery and SternaBra for women; Parasol Medical Cultivate quality assurance products for aseptic procedures; and NDI disposable marking spheres for surgical navigation and tracking. The company also acquired the Critical Concepts Inc. neonatal distribution product line in 2020, expanding its NICU offerings. Summit operates primarily in the United States, serving hospitals, critical care units, dialysis centers, and surgical facilities. The company emphasizes clinician-trusted, easy-to-use solutions with measurable clinical outcomes such as reduced complications, faster patient recovery, and improved safety. Products are designed for both acute hospital settings and post-operative care environments.

Boston Orthotics & Prosthetics (Boston O&P) is a pediatric-focused provider of custom orthotics and prosthetics with over 50 years of clinical experience. The company is the world's leading manufacturer of the Boston Brace, the most widely prescribed non-surgical scoliosis treatment system. Core product lines include scoliosis and spine orthoses (particularly the Boston Brace for adolescent idiopathic scoliosis), plagiocephaly treatment bands (cranial orthoses for positional head deformities in infants), dynamic movement orthoses for neuromuscular conditions, lower limb orthoses, and custom prosthetic devices. Boston O&P operates a network of clinical centers located within top-rated children's hospitals nationwide, staffed by certified orthotists and prosthetists. The company also maintains a Certified Partner Program that trains and credentials external providers to fit and dispense Boston O&P products, ensuring standardized clinical outcomes. Educational services include continuing professional education, online eLearning modules, and clinical support. Boston O&P was acquired by OrthoPediatrics Corp in 2024, expanding its market reach within the pediatric orthopedic device sector. The company serves pediatric and adult patient populations with evidence-based, non-surgical treatment solutions for scoliosis, developmental conditions, and mobility disorders.

Alcresta Therapeutics develops enzyme-based products for rare disease patients requiring enteral nutrition. The company specializes in addressing fat malabsorption disorders, particularly exocrine pancreatic insufficiency, in pediatric and adult patients receiving tube feeding at home or in clinical settings. Alcresta's primary product, RELiZORB® cartridge containing iLipase® (immobilized lipase), is a patented microbead enzyme technology designed to mimic pancreatic lipase function and facilitate fat digestion and absorption in enterally fed patients. RELiZORB is indicated for patients with cystic fibrosis, short bowel syndrome, pancreatitis, digestive cancers, and other conditions causing fat malabsorption. The product is the first and only enzyme product formulated for use directly in enteral feeding systems. Alcresta has received FDA clearance, including recent expanded use authorization for neonates and infants (November 2025). The company conducts clinical research to support product efficacy, including Phase 3 exploratory studies and real-world evidence registries demonstrating growth improvements in pediatric patients. Manufacturing capabilities include enzyme immobilization technology and cartridge formulation. Alcresta serves hospital and home care markets, targeting gastroenterology, pediatrics, and rare disease specialties.

Aegis Star Dental Technologies manufactures specialized orthodontic devices, specifically the Keles Keyless Expander (KKE), a palatal expander designed for maxillary expansion and protraction. The KKE distinguishes itself through an integrated activation arm that eliminates the need for a separate key, reducing treatment complexity and improving patient compliance. The device features a compact design enabling deep placement for true skeletal expansion while prioritizing patient comfort and safety. The product is particularly designed to serve pediatric patients, including those with physical or cognitive challenges, promoting inclusivity in orthodontic care. The KKE has been featured in the Journal of Clinical Orthodontics (JCO) and represents a clinical advancement addressing limitations of traditional palatal expansion devices. Manufacturing capabilities include 3D-printed hybrid construction. The company positions this device as a new standard of care in orthodontic expansion therapy, with emphasis on reducing treatment duration, eliminating patient frustration associated with key management, and improving overall patient-dentist relationships through enhanced treatment experience.

Rebion, Inc. commercializes Neural Performance Scanning (NPS), a proprietary technology platform that measures neurophysiologic mechanisms of the optic nerve/brain continuum through retinal scanning. The company's primary product, Blinq®, is an FDA-cleared portable point-of-care neural performance scanner designed for pediatric vision screening. Blinq directly detects micro-strabismus and amblyopia (lazy eye) by quantifying bilateral fixation and saccadic eye movements, achieving up to 100% sensitivity and over 90% specificity in clinical evaluations. The device performs a 3-second neural performance scan capable of detecting binocularity impairments associated with as little as 1-degree misalignment. Rebion's technology is supported by peer-reviewed clinical studies and research conducted at major medical institutions. The company also develops Traq™, an investigational device leveraging NPS to measure visual tracking impairments for clinical research purposes (currently not available for sale in the United States). Rebion serves diverse markets including community screeners, schools and administrators, clinical staff, parents, and caregivers. The platform enables early disease detection, intervention, and customized treatment across clinics, schools, and public health initiatives, reducing unnecessary referrals while improving diagnostic accuracy and patient outcomes.

New England Orthodontic Laboratory (NEOLab) is a Massachusetts-based orthodontic appliance manufacturer and laboratory service provider founded in 1976. The company specializes in design, fabrication, and delivery of orthodontic appliances and pediatric devices for practicing orthodontists. NEOLab operates a technician-staffed laboratory equipped with SLS 3D metal printing and 3D printing technology, enabling rapid turnaround production including 24-hour service options. The company's product portfolio includes SLS 3D-printed metal appliances with chairside adjustability, Essix retainer systems, and TAD-based (temporary anchorage device) appliances. NEOLab emphasizes workflow efficiency and chair-time reduction for orthodontic practitioners through solutions-oriented product design and digital lab slip systems. The laboratory maintains a focus on quality control, customer service, and technical support for orthodontic practices. The company serves orthodontists throughout the United States and has received industry recognition as Best Ortho Lab of 2024.

ACRA-CUT, Inc., located in Acton, Massachusetts, is a specialized manufacturer of neurosurgical instruments founded in 1981. The company is recognized as a leader in the research, development, and manufacture of cranial perforators for open neurosurgery. ACRA-CUT designs and produces a comprehensive range of cranial perforators in multiple models and sizes to address bone variations in both adult and pediatric procedures. Their product portfolio includes the ACRA-CUT Scalp Clip System, a reusable scalp clip gun with disposable clip cartridges in various clamping forces for hemostasis in both adult and pediatric applications. The company also manufactures spiral cranioblades optimized for low-speed applications, hand instruments including dura separators, cranioblade kits, and distraction screws for neurosurgical applications. Product lines include Smart Drill, Express 100, and Express 120 models. ACRA-CUT serves neurosurgeons, surgical centers, and hospital operating rooms in the United States. The company maintains a strong commitment to manufacturing safety and product design quality for neurosurgical patients. While specific regulatory certifications are not detailed on the fetched site content, the company's long operational history and surgical instrument focus suggest compliance with applicable medical device regulations.

Little Sparrows Technologies is an award-winning startup dedicated to advancing newborn care through innovative medical devices designed for resource-limited settings. The company's flagship product, the Bili-Hut™, is a portable, battery-operable neonatal phototherapy device for treating jaundice in newborns. The Bili-Hut features neonatologist-designed engineering, 180° wraparound light exposure, and enables treatment within 24 hours while supporting family-centered care and breastfeeding. The company also manufactures the Bili-Ruler™, a jaundice screening tool using digital image processing, and developmental care products including swaddling and positioning aids. All innovations focus on clinical effectiveness in low-resource environments. The Bili-Hut has received recognition from the Gates Foundation, USAID, and the National Institutes of Health, with recent randomized clinical pilot trial results validating its efficacy.

Luminopia Inc. is an FDA-cleared digital therapeutics company specializing in VR-based treatment for pediatric amblyopia (lazy eye) in children aged 4–12. The company delivers its prescription-only Luminopia software through commercially available VR headsets, enabling patients to receive binocular vision therapy while watching curated TV content instead of traditional patching. The treatment regimen requires one hour daily, six days weekly, with clinical trials demonstrating significant vision improvement within 4–12 weeks. Luminopia is prescribed by ophthalmologists, optometrists, and orthoptists; the company handles fulfillment, patient support, and compliance monitoring. Designed for at-home use alongside corrective lenses, Luminopia achieved 94% parental preference over conventional patching and demonstrated 85% median treatment completion rates, addressing the long-standing compliance challenges in amblyopia management.